Source: Annual Congress 2010 - Management of airway disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. McLaughlin, C. de Moor, G. Reardon, P. Navaratnam (Columbus, United States Of America). Comparative evaluation of desloratadine versus levocetirizine in managing patients with comorbid rhinitis and asthma in the United Kingdom. Eur Respir J 2010; 36: Suppl. 54, 4573

Member's Comments

No comment yet.

Related content which might interest you: Economic evaluation of beclomethasone/formoterol versus budesonide/formoterol in the treatment of patient with moderate-severe asthma in Spain Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment Year: 2008 Efficacy of montelukast in Indian patients having chronic persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 372s Year: 2003 Efficacy of cetirizine and pseudoephedrine in school children with seasonal allergic rhinitis and mild asthma Source: Eur Respir J 2002; 20: Suppl. 38, 526s Year: 2002 Effects of loratadine and its generic on symptoms of asthma and rhinitis Source: Annual Congress 2008 - Allergy and immunology of asthma and beyond Year: 2008 Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006 Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care Year: 2007 Efficacy of the using budesonide/formoterol in patients with bronchial asthma (BA): the study of routine clinical practice Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006 Safety of once-daily QMF149 in patients with persistent asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma – real life experience from Czech Anti-IgE Registry Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Safety and efficacy of omalizumab in children with allergic asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting Source: International Congress 2017 – Asthma management Year: 2017 Pharmacoeconomic analysis of beclomethasone/formoterol versus fluticasone/salmeterol in the treatment of moderate-severe asthma in Spain Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment Year: 2008 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Association between allergic rhinitis and hospital resource use among asthmatic children in Norway Source: Eur Respir J 2002; 20: Suppl. 38, 335s Year: 2002 Asthma exacerbations in children receiving montelukast vs. other controllers in Italy Source: Eur Respir J 2005; 26: Suppl. 49, 618s Year: 2005 Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017 Safety of formoterol in children and adolescents: experience from asthma clinical trials Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008